Navigation Links
BCM-95 Demonstrates Superior Anti-Inflammatory Effects
Date:9/16/2010

GREEN BAY, Wis., Sept. 16 /PRNewswire/ -- Top researchers at the Gastrointestinal Cancer Research Lab at Baylor University Medical Center in Dallas are exploring the clinical applications of BCM-95®, a new patented extract of curcumin with unprecedented potency, and bioavailability.

Previous studies have shown that BCM-95 curcumin was 7-10 times more bioavailable than other forms of curcumin, and had a retention time in the bloodstream between 8 to 12 hours.(1) At all points in the study, BCM-95 curcumin levels were higher than any other form of curcumin tested. This superior absorption and retention is attained by a patented process that involves homogenization and micronization with turmeric essential oil which is then bound to natural plant phospholipids.

"We have the most fascinating and convincing scientific laboratory evidence from thousands of  studies finding that curcumin has potent anti-inflammatory properties," said Ajay Goel, Ph.D., Investigator at the Gastrointestinal Cancer Research Lab at Baylor University. "Abundant data point to the pain-relieving and anti-inflammatory efficacy of curcumin – and these benefits are essentially drawn from its ability to suppress and inhibit the activities of two major pro-inflammatory targets within our cells: NF-kB and COX-2." Dr. Goel's  group was the first to demonstrate that curcumin acts as a specific COX-2 inhibitor, and hence, plays an important role in not only alleviating everyday pain, but has the potential to prevent many chronic diseases that manifest themselves in the background of increased inflammation.

While curcumin holds huge promise as an anti-inflammatory, pain relieving substance, in the human body curcumin is poorly absorbed.  "However, BCM-95 amplifies and potentiates its effectiveness," Dr. Goel explained. "Not only is BCM-95 curcumin absorbed up to 10 times better than conventional curcumin, it also is retained in the body longer. Currently, we have several scientific studies underway in our laboratory on BCM-95, and we are extremely encouraged by the new promising discoveries we are making with this miracle herb."

According to Dr. Goel, inflammation is a factor in 80-90% of all disease. Curcumin demonstrates superior antioxidant and anti-inflammatory effects, and provides liver and heart-protective benefits as well. It is a potent anti-bacterial, anti-fungal, anti-viral, anti-allergenic, and has anti-tumor and anti-cancer properties.

EuroPharma, Inc. is the exclusive distributor of BCM-95® in the U.S. through both the health food store and professional distribution channels. EuroPharma offers clinically proven and effective nutritional supplements and natural remedies that improve the health of America. At EuroPharma, Our Passion is Your Health®. For more information on EuroPharma, visit www.EuroPharmaUSA.com.

(1) Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyala S. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax) a novel bioenhanced preparation of curcumin. Ind J Pharm Sci. 2008. 2008;70(4):445-450.


'/>"/>
SOURCE EuroPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EuroPharma Exclusive Distributor of BCM-95 and BosPure
2. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
7. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
8. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their ... have been used to remove decayed dental matter, and that teeth were then filled ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between ... relative proportion of young people involved in violence in the United States. The ...
(Date:4/21/2017)... ... April 21, 2017 , ... Brady (NYSE:BRC), a ... B-595 and B-7569 vinyl label materials received certification for the ... are tested to remain intact and legible, for use on chemical drums shipped by ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The adage ... Flex House, the next project in the company’s esteemed VISION House demonstration project series. ... use exactly the amount of resources they need to live affordably and abundantly without ...
(Date:4/21/2017)... ... 21, 2017 , ... The Hong Kong Polytechnic University (PolyU) launched today the ... education institutions in Hong Kong to support teaching, learning and research. It is also ... of facilities in Hong Kong. , With an area of 620 square metres ...
Breaking Medicine News(10 mins):